Abstract
Community health systems (CHS) provide over 50% of cancer care in the US. Biomarker testing rates among patients with advanced Non-Squamous (NSQ) Non-Small Lung Cancer (NSCLC) patients at CHS are not widely published. This analysis describes testing rates for clinically relevant biomarkers within this population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.